Please login to the form below
Oseni
This page shows the latest Oseni news and features for those working in and with pharma, biotech and healthcare.
Forest Labs agrees $1.46bn deal to buy Furiex
Furiex also has a stable of marketed drugs for diabetes including Nesina (alogliptin) and fixed-dose combination therapies Oseni/Liovel (alogliptin/pioglitazone) and Kazan (alogliptin/metformin), which are sold by Takeda,
Latest news
-
FDA investigates pancreas risk of diabetes drugs
Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.
-
Takeda gets FDA approval for alogliptin franchise in diabetes
Comprises Nesina, Oseni and Kazano. Takeda was celebrating at the end of last week after the FDA granted approval to three of its diabetes drug candidates. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
PMHub
Novasecta
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...
Latest intelligence
- A roadmap to the successful treatment of Alzheimer’s disease
- Building on past research to learn more about the disease and how to treat it...
- Article: Like, Like, Like: Harnessing the power of social media insights
- ...
- Its Know Your Numbers week
- Do you know yours?...
Quick links
Infographics
